Anlotinib with fulvestrant for advanced, HR-positive, HER2-negative breast cancer
Part of Cancer clinical trials.
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- Your breast cancer is HR-positive and HER2-negative, and it is locally advanced or metastatic
- Your cancer must have at least one measurable spot on scans
- You can be expected to live at least 12 weeks, and your general condition is good (ECOG 0–1)
- You have had limited prior metastatic chemotherapy (no more than one treatment course)
- Your organs and blood tests are in a safe range (including blood counts, liver, and kidney function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
This trial tests a combination of three drugs—neratinib (a pill), fulvestrant (an injection), and eribulin (chemotherapy)—for people with advanced breast cancer that is both HER2-positive and hormone receptor-positive, and that has not responded to the drug T-DXd.
This trial tests a combination of two drugs—entinostat and fulvestrant—for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to standard hormone therapy and a CDK4/6 inhibitor. The goal is to see if this combo can help shrink tumors or slow their growth.
Hear when a new Breast Neoplasm Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.